What is Pertuzumab?
Category: Prescription Drugs
Most popular types: Perjeta
See also: Docetaxel-carboplatin-trastuzumab-pertuzumab Docetaxel-trastuzumab-pertuzumab (DHP) Doxorubicin-cyclophosphamide-docetaxel-trastuzumab-pertuzumab Doxorubicin-cyclphophosphamide-paclitaxel-trastuzumab-pertuzumab (AC-THP) Paclitaxel-trastuzumab-pertuzumab (THP)
Pertuzumab is a HER2/neu receptor blocker that is used in combination with other chemotherapy agents for the treatment of patients with HER2-positive, metastatic breast cancer.
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Breast cancer | 5 | 0 | |
| Lung cancer | 1 | 0 | |
| Nausea | 1 | 0 | |
| Participate in clinical trial | 1 | 1 |
- Major
- Moderate
- Slight
- None
- Can't tell
Side effects
Side effects as an overall problem
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 0 | |
| Moderate | 0 | |
| Mild | 1 | |
| None | 0 |
Commonly reported side effects and conditions associated with Pertuzumab
| Side effect | Patients | Percentage |
|---|---|---|
| Chronic fatigue | 1 |
Why patients stopped taking Pertuzumab
Multiple reasons could be selected
| Reason | Patients | Percentage |
|---|---|---|
| Course of treatment ended | 1 | |
| Other | 1 |
Duration
Stopped taking Pertuzumab
| Duration | Patients | Percentage |
|---|---|---|
| 1 - 6 months | 1 | |
| 2 - 5 years | 1 |
What people switch to and from
Patients stopped taking Pertuzumab and switched to:
| Treatment | Patients | Percentage |
|---|---|---|
| Ado-trastuzumab emtansine (Kadcyla) | 1 | |
| Bevacizumab (Avastin) | 1 | |
| Cisplatin | 1 | |
| Paclitaxel (Taxol) | 1 |
Last updated: